endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-2-19endofocus-91Research ArticleСтатьи70 лет применения метформина. Успехи и достижения70 years of metformin use. Success and achievementshttps://orcid.org/0000-0002-6826-5924ТепловаА. С.TeplovaA. S.

Теплова Анна Сергеевна – ассистент кафедры эндокринологии лечебного факультета 

117997, Москва, улица Островитянова, д. 1

Anna S. Teplova, assistant of the department of endocrinology medical faculty

Moscow

anna_kochina_@mail.ruhttps://orcid.org/0000-0002-3529-2758БогачеваТ. Л.BogachevaT. L.

Богачева Татьяна Леонидовна –  ассистент кафедры эндокринологии

117997, Москва, улица Островитянова, д. 1

Tatiana L. Bogacheva, assistant of the department of endocrinology medical faculty

Moscow

bogacheva@68gkb.ruТимофееваА. Е.TimofeevaA. E.

Тимофеева Анастасия Евгеньевна –  студентка лечебного факультета

117997, Москва, улица Островитянова, д. 1

Anastasia E. Timofeeva, student of the faculty of general medicine

Moscow

https://orcid.org/0009-0002-7139-6893СтегачеваД. С.StegachevaD. S.

Стегачева Дина Сергеевна –  студентка лечебного факультета

117997, Москва, улица Островитянова, д. 1

Dina S. Stegacheva, student of the faculty of general medicine

Moscow

dstegacheva@mail.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University202413052024526265Copyright © Теплова А.С., Богачева Т.Л., Тимофеева А.Е., Стегачева Д.С., 20242024Теплова А.С., Богачева Т.Л., Тимофеева А.Е., Стегачева Д.С.Teplova A.S., Bogacheva T.L., Timofeeva A.E., Stegacheva D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/91

Первые упоминания о метформине появились около 100 лет назад. С того момента эволюция мнений о метформине претерпела значительные изменения. В последние десятилетия активного использования данного препарата открылся широкий спектр положительных свойств метформина как в отношении метаболического здоровья, так и касательно совершенно неожиданных аспектов длительности и качества жизни. Данный обзор сфокусирован на актуальных свойствах метформина и перспективах повышения популярности данного препарата среди пациентов и медицинских специалистах с точки зрения потенциальной пользы для здоровья населения.

The first mention of metformin appeared about 100 years ago. Since then, the evolution of opinions about metformin has undergone significant changes. In recent decades, the active use of this drug has revealed a wide range of positive properties of metformin both in relation to metabolic health and completely unexpected aspects of longevity and quality of life. This review focuses on the current properties of metformin and the prospects for increasing the popularity of this drug among patients and medical professionals in terms of potential public health benefits.

метформининсулинорезистентностьнарушения углеводного обменасахарный диабет 2 типасахароснижающие препаратыmetformininsulin resistancedisorders of carbohydrate metabolismtype 2 diabetes mellitushypoglycemic drugsReferencesЮбилей МЕТФОРМИНА: 2007 год – 50 лет применения. Сахарный диабет. 2007; 10(4):71–71. https://doi.org/10.14341/2072–0351–5872Юбилей МЕТФОРМИНА: 2007 год – 50 лет применения. Сахарный диабет. 2007; 10(4):71–71. https://doi.org/10.14341/2072–0351–5872Дедов И. И., Шестакова М. В., Майоров А. Ю., Мокрышева Н. Г., Андреева Е. Н., Безлепкина О. Б. et al. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042Дедов И. И., Шестакова М. В., Майоров А. Ю., Мокрышева Н. Г., Андреева Е. Н., Безлепкина О. Б. et al. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042American Diabetes Association Professional Practice Committee: 15 Management of diabetes in pregnancy: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45:232–43. doi: 10.2337/dc22-S015American Diabetes Association Professional Practice Committee: 15 Management of diabetes in pregnancy: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45:232–43. doi: 10.2337/dc22-S015Diabetes Canada Clinical Practice Guidelines Expert Committee, D. S. Feig, H. Berger, L. Donovan, A. Godbout, T. Kader, E. Keely et al. Diabetes and pregnancy. Can. J. Diabetes 42, 255–82 (2018). 10.1016/j.jcjd.2017.10.038Diabetes Canada Clinical Practice Guidelines Expert Committee, D. S. Feig, H. Berger, L. Donovan, A. Godbout, T. Kader, E. Keely et al. Diabetes and pregnancy. Can. J. Diabetes 42, 255–82 (2018). 10.1016/j.jcjd.2017.10.038Sciacca L, Bianchi C, Burlina S, Formoso G, Manicardi E, Sculli MA, et al. Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: metformin use in pregnancy. Acta Diabetol. 2023; 60:1421–37. doi: 10.1007/S00592-023-02137-5/TABLES/15Sciacca L, Bianchi C, Burlina S, Formoso G, Manicardi E, Sculli MA, et al. Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: metformin use in pregnancy. Acta Diabetol. 2023; 60:1421–37. doi: 10.1007/S00592-023-02137-5/TABLES/15Nguyen L, Chan SY, Teo AKK. Metformin from mother to unborn child – Are there unwarranted effects? EBioMedicine. 2018 Sep;35:394–404. doi: 10.1016/j.ebiom.2018.08.047Nguyen L, Chan SY, Teo AKK. Metformin from mother to unborn child – Are there unwarranted effects? EBioMedicine. 2018 Sep;35:394–404. doi: 10.1016/j.ebiom.2018.08.047LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021 Jan 28;42(1):77–96. doi: 10.1210/endrev/bnaa023LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021 Jan 28;42(1):77–96. doi: 10.1210/endrev/bnaa023Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019 Oct;15(10):569–589. doi: 10.1038/s41574-019-0242-2Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019 Oct;15(10):569–589. doi: 10.1038/s41574-019-0242-2Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-t reated patients. Diabetes Obes Metab. 2012;14:518–522. doi: 10.1111/j.1463-1326.2011.01550.xFadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-t reated patients. Diabetes Obes Metab. 2012;14:518–522. doi: 10.1111/j.1463-1326.2011.01550.xMannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care. 2001;24:489–494. doi: 10.2337/diacare.24.3.489Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care. 2001;24:489–494. doi: 10.2337/diacare.24.3.489Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008; 149:2341–2351. doi: 10.1210/en.2007-1142Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008; 149:2341–2351. doi: 10.1210/en.2007-1142Huang Y, Lou X, Jiang C, Ji X, Tao X, Sun J, Bao Z. Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022 Nov 17; 13:1044030. doi: 10.3389/fendo.2022.1044030Huang Y, Lou X, Jiang C, Ji X, Tao X, Sun J, Bao Z. Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022 Nov 17; 13:1044030. doi: 10.3389/fendo.2022.1044030McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016 Mar;59(3):426–35. doi: 10.1007/s00125-015-3844-9McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016 Mar;59(3):426–35. doi: 10.1007/s00125-015-3844-9Shu Y, Li W, Hu Q, Xiong D. Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review. Medicine (Baltimore). 2023 Dec 15;102(50): e36478. doi: 10.1097/MD.0000000000036478Shu Y, Li W, Hu Q, Xiong D. Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review. Medicine (Baltimore). 2023 Dec 15;102(50): e36478. doi: 10.1097/MD.0000000000036478Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805Vallianou NG, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens). 2019 Jun;18(2):141–144. doi: 10.1007/s42000-019-00093-wVallianou NG, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens). 2019 Jun;18(2):141–144. doi: 10.1007/s42000-019-00093-wZhou C, Peng B, Qin Z, Zhu W, Guo C. Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway. BMC Neurosci. 2021 Nov 26;22(1):73. doi: 10.1186/s12868-021-00678-5Zhou C, Peng B, Qin Z, Zhu W, Guo C. Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway. BMC Neurosci. 2021 Nov 26;22(1):73. doi: 10.1186/s12868-021-00678-5Huang H, Lee SH, Sousa-L ima I, et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018; 128:5335–5350. doi: 10.1172/JCI63562Huang H, Lee SH, Sousa-L ima I, et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018; 128:5335–5350. doi: 10.1172/JCI63562Tang X, Li J, Xiang W, et al. Metformin increases hepatic leptin receptor and decreases steatosis in mice. J Endocrinol. 2016; 230:227–237. doi: 10.1530/JOE-16-0142Tang X, Li J, Xiang W, et al. Metformin increases hepatic leptin receptor and decreases steatosis in mice. J Endocrinol. 2016; 230:227–237. doi: 10.1530/JOE-16-0142Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. Gut Liver. 2021 Nov 15;15(6):827–840. doi: 10.5009/gnl20367Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. Gut Liver. 2021 Nov 15;15(6):827–840. doi: 10.5009/gnl20367Li YL, Li XQ, Wang YD, Shen C, Zhao CY. Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. Biochem Biophys Res Commun. 2019; 513:64–72. doi: 10.1016/j.bbrc.2019.03.077Li YL, Li XQ, Wang YD, Shen C, Zhao CY. Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. Biochem Biophys Res Commun. 2019; 513:64–72. doi: 10.1016/j.bbrc.2019.03.077Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, Lønnebotn M, Hestvold KV, Zabielska R, Hirschberg AL, Trouva A, Thorarinsdottir S, Hjelle S, Berg AH, Andræ F, Poromaa IS, Mohlin J, Underdal M, Vanky E. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Apr;7(4):256–266. doi: 10.1016/S2213-8587(19)30002-6Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, Lønnebotn M, Hestvold KV, Zabielska R, Hirschberg AL, Trouva A, Thorarinsdottir S, Hjelle S, Berg AH, Andræ F, Poromaa IS, Mohlin J, Underdal M, Vanky E. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Apr;7(4):256–266. doi: 10.1016/S2213-8587(19)30002-6Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). 2020 Apr 16; 11:191. doi: 10.3389/fendo.2020.00191Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). 2020 Apr 16; 11:191. doi: 10.3389/fendo.2020.00191Chen F, Wei G, Wang Y, Liu T, Huang T, Wei Q, Ma G, Wang D. Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. BMC Public Health. 2019 Aug 7;19(1):1063. doi: 10.1186/s12889-019-7392-yChen F, Wei G, Wang Y, Liu T, Huang T, Wei Q, Ma G, Wang D. Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. BMC Public Health. 2019 Aug 7;19(1):1063. doi: 10.1186/s12889-019-7392-yPomilio C, Pérez NG, Calandri I, Crivelli L, Allegri R; ADNI Alzheimer’s Disease Neuroimaging Initiative; Sevlever G, Saravia F. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. Geroscience. 2022 Jun;44(3):1791–1805. doi: 10.1007/s11357-022-00568-6Pomilio C, Pérez NG, Calandri I, Crivelli L, Allegri R; ADNI Alzheimer’s Disease Neuroimaging Initiative; Sevlever G, Saravia F. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. Geroscience. 2022 Jun;44(3):1791–1805. doi: 10.1007/s11357-022-00568-6Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942

The authors declare that there are no conflicts of interest present.